Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases characterized by an excessive production of blood cells by hematopoietic precursors and are often accompanied by myelofibrosis. The V617F somatic mutation in the Janus kinase 2 gene (JAK2) has recently been found in the majority of patients with polycythemia vera, in 60-70% of patients with essential thrombocythemia and in approximately 50% of patients with primary myelofibrosis (PMF). 1 The expression of JAK2 V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow (BM) transplant model. 2 In addition, a gain-of-function c-MPL W515 mutation was described in nearly 10% of patients with JAK2 V617F-negative PMF. However, the mechanism responsible for MPN and for the formation of myelofibrosis in patients without the JAK2 or c-MPL mutation is still unclear.
The TEL gene is a member of the ets family transcription factor located on the 12p13 chromosome. It is well known that TEL forms fusion genes with more than 20 partner genes in hematological and even nonhematological malignancies. 3 A major group of TEL fusion partners includes protein tyrosine kinases (PTK) and transcriptional factors such as RUNX1 (AML1) in childhood leukemia. The former group includes fusions of TEL to ABL, ARG, JAK2, NTRK3, FGFR3, PDGFR-a and Syk kinase, which have been found in MPN and other hematological malignancies. The most precisely defined mechanism of transformation by TEL-PTK fusion products is through a constitutive kinase activation by oligomerization of TEL-PTK mediated by the PNT domain of TEL in TEL-PTK chimeras.
Lyn kinase is a specific member of the src family of kinases and is an important component in cytokine signal transduction in a variety of cells; it is also reported to have a key role in the growth and apoptotic regulation of hematopoietic cells. 4 Donato et al. 5 reported that Lyn kinase is highly expressed and activated in imatinib-resistant K562 cells and in samples from chronic myeloid leukemia patients who progressed to a blastic crisis or to an accelerated phase during imatinib treatment. In addition, Lyn is constitutively activated in acute myeloid leukemia and in BCR-ABL-positive acute lymphoblastic leukemia. However, there has been no report of the src family tyrosine kinase gene fusing to TEL and a possible association with MPN.
In this study, we identified a novel TEL-Lyn fusion gene in PMF bearing the chromosomal abnormality ins (12;8)(p13;q11q21), and analyzed its mitogenic and clonogenic capacity.
A 21-year-old man developed a huge abdominal mass, pain and high fever and was admitted to a hospital in November 2004. His physical examination revealed a huge splenomegaly reaching to his pelvic cavity. Laboratory findings disclosed white blood cells 25.5 Â 10 9 /l, hemoglobin 6.9 g per 100 ml and platelets 24 Â 10 9 /l. The peripheral blood (PB) smear showed leuko-erythroblastosis. The BM was a dry tap and the BM biopsy specimen revealed a hypercellular marrow with increased reticulin fiber in silver staining. A cytogenetic study of PB showed that all examined cells had an abnormal karyotype of 46 XY, ins (12;8)(p13;q11q21). The reverse transcription-PCR analysis for bcr/abl transcript was negative. The patient was diagnosed with PMF. The disease was refractory to chemotherapy, splenic irradiation or imatinib, and in spite of undergoing allogeneic peripheral blood stem cell transplantation from his HLA-identical brother twice, he died of blastic transformation in October 2005.
Owing to the fact that the TEL gene is located on the 12p13 chromosome and that the Lyn kinase gene, which is located on 8q13 region, is the only known tyrosine kinase gene between the 8q11 and 8q21 region, we hypothesized that TEL and Lyn might be associated with the pathogenesis of his disease by the formation of a fusion gene. To test this hypothesis, we designed specific primers for the TEL and Lyn genes and identified a novel TEL-Lyn fusion transcript by reverse transcription-PCR. With written informed consent, total RNA was extracted from PB mononuclear cells from the patient and was tested for the TEL-Lyn fusion transcript by reverse transcription-PCR. A 778 bp band of the TEL-Lyn fusion gene was detected in the patient sample and was not detected in healthy controls or in two patients with myelodysplasia or eosinophilia (Figure 1a) . Using primers at the 5 0 untranslated region of TEL and the 3 0 untranslated region of Lyn, we detected 1911 bp fusion products. A sequencing analysis of PCR products revealed that the TEL and Lyn genes were fused at the break points of 1010 and 638 bp from the start codon of each gene, respectively. This transcript had no other mutation, insertion, deletion or frame shift. The whole structure of the TEL-Lyn fusion gene is shown in Figure 1b . The fusion gene has the PNT domain of TEL and the PTK domain of Lyn. No reciprocal Lyn-TEL fusion gene was detected in the patient's sample. There was no JAK2 V617F, JAK2 exon12 or c-MPL W515 mutation. Thereafter, we examined the expression of the TEL-Lyn fusion protein by western blot analysis. A 75 kDa protein was detected in FLAG-TEL-Lyn-transfected Ba/F3 cells using an anti-FLAG antibody Letters to the Editor immunoprecipitation with anti-FLAG antibody (Figure 1d) . The TEL-Lyn fusion protein was constitutively tyrosine phosphorylated without any stimulation.
To analyze the mitogenic properties of the TEL-Lyn fusion gene, we introduced the TEL-Lyn fusion gene to murine interleukin (IL)-3-dependent Ba/F3 cells using a retrovirus vector as previously described. 6 We identified that the Ba/F3 cells expressing the TEL-Lyn gene attained IL-3-independent proliferation (Figure 2a) . We next examined the effect of tyrosine kinase inhibitors (TKIs) on TEL-Lyn-induced proliferation. The proliferation of Ba/F3 cells expressing the TEL-Lyn gene was hardly suppressed even with a high concentration of imatinib (5000 nM), but was completely suppressed with a lower concentration of dasatinib (2 nM) (Figure 2b) . Moreover, tyrosine phosphorylation of TEL-Lyn was hardly suppressed with 1000 nM imatinib but was completely suppressed with 10 nM dasatinib (Figure 2c) . Thereafter, we examined the effect of the TEL-Lyn fusion gene on colony formation of hematopoietic stem cells (HSCs). Mouse HSCs (CD34 -c-Kit þ Sca-1 þ lineage marker -: CD34 -KSL cells) were purified from BM cells of 8-week-old C57BL/6 (B6) mice as previously described.
6 CD34 -KSL HSC fractions are highly enriched for long-term repopulation of HSCs. CD34
-KSL HSCs expressing the TEL-Lyn gene formed colonies without any exogenous growth factors such as SCF, IL-3, EPO or TPO, whereas the control HSCs had no colony formation (Figure 3a) . The colonies generated from the TEL-Lyn-transduced CD34 -KSL cells consisted of all myeloid lineage cells including neutrophils, macrophages, erythroblasts and megakaryocytes and did not exhibit an accumulation of blastic cells (Table 1) . These colonies were suppressed more significantly with 20 nM dasatinib than with an even higher concentration of imatinib (Figure 3b) .
To examine the transformation properties of the TEL-Lyn fusion gene in vivo, the TEL-Lyn gene or control vectortransduced CD34 -KSL HSCs from C57BL/6 mice, congenic for the Ly5.1 locus (B6-Ly5.1 mice), were transplanted into lethally irradiated B6-Ly5.2 mice. All the 10 mice transplanted with CD34 -KSL cells expressing the TEL-Lyn gene died within 4 weeks after transplantation, whereas all control mice remained healthy over 8 weeks (Figure 4a ). The PB cell count of three TEL-Lyn group mice on day 25 after transplantation had a significantly higher WBC count and marked neutrophilia (data not shown). The spleen cells of these mice had the expression of the TEL-Lyn fusion protein (Figure 4b ) and huge hepatosplenomegaly was observed (Figures 5a and b) . A histological examination of the spleen revealed that the spleen structure was destroyed with marked infiltration of leukocytes and massive fibrosis in the TEL-Lyn group (Figures 5c and d) . The mice transplanted with control HSCs showed a normal range of BM reconstitution (Figures 5e and g ), whereas marked fibrosis of BM was observed in mice that died at 4 weeks after transplantation of TEL-Lyn þ HSCs (Figures 5f and h) .
Abe et al. 7 screened TEL-cDNA fusion libraries in a retrovirus vector for transforming potentials according to the cytokineindependent growth of 32D cells, and cloned 25 independent artificial fusion proteins with seven kinds of protein kinase genes as fusion partners. Among them, 12 clones were TEL-Lyn fusion genes and one clone with a break point of Lyn at 696 bp showed the highest transforming capacity. Because the deletion of the PNT domain of this TEL-Lyn fusion protein resulted in a loss of transforming activity, this transformation capacity of the TEL-Lyn fusion protein is thus considered to be dependent on the PNT domain of TEL. These results suggest that the TEL-Lyn fusion protein of this patient is constitutively activated by dimerization through the PNT domain of TEL and it is highly responsible for the pathogenesis of the disease.
Lyn is considered to be a negative regulator of normal myeloid hematopoiesis, except for the terminal maturation of erythroblasts, and can have both positive and negative roles in B cells. 4 Among the Src family of kinases, Lyn is highly expressed and constitutively phosphorylated at a high level in acute myeloid leukemia cells. The high level of Lyn expression and its aberrant activation in leukemic cells possibly cause it to switch Abbreviations: E, erythrocyte; HSCs, hematopoietic stem cells; M, megakaryocyte; m, macrophage; n, neutrophil.
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Control from being a negative to a positive regulator of cell proliferation, as recently proposed in Philadelphia chromosome-positive acute lymphoblastic leukemia. 8 We observed the mitogenic properties of the TEL-Lyn fusion gene by transducing TEL-Lyn into Ba/F3 cells. In contrast, if the TEL-Lyn fusion gene was transduced into murine CD34 -KSL HSCs, which are a highly enriched fraction for long-term BM repopulating HSCs, TEL-Lyn conferred a cytokine-independent clonogenic capacity on them and promoted their differentiation along all kinds of myeloid lineages and caused an MPN-like disease with massive myelofibrosis in a very short period of time.
Other noteworthy facts that we demonstrated in our analysis were that dasatinib suppressed the proliferation and differentiation of TEL-Lyn-transfected cells, although imatinib did not. Dasatinib is a synthetic small-molecule inhibitor of the src family of kinases such as Lyn, CSK, FGR and HCK, other than ABL, and was noticed as one of the second generation TKIs after imatinib. The high sensitivity of TEL-Lyn-transformed cells to dasatinib suggests that Lyn might be a molecular target in MPN or myelofibrosis with the TEL-Lyn fusion gene.
In summary, we identified a novel TEL-Lyn fusion transcript in a patient with PMF who had a chromosomal abnormality of ins (12;8)(p13;q11q21). Introduction of the TEL-Lyn fusion gene into HSCs results in a rapid development of myelofibrosis, as well as in myeloproliferative transformation. Lyn kinase was constitutively activated, presumably by TEL-induced oligomerization. These data imply for the first time that rearranged or activated Lyn kinase is involved in the pathogenesis of MPN and myelofibrosis. Further extensive study on the role of Lyn in MPN may therefore help to elucidate the clinical MPN entity in a more complete manner. 
